Introduction and Objectives: MHE is related to a higher risk of accidents and deterioration in the quality of life; it can be detected with PHES and CFP. There is currently insufficient evidence that treatment with oral LOLA improves performance in PHES and CFP in patients with MHE. This study aimed to verify the response and safety of LOLA treatment in a real-life cohort of patients with MHE. Materials and Methods: Cirrhotic patients in the Hepatology clinic diagnosed with MHE received LOLA 6 grams three times a day for three days and were reassessed with PHES and CFP. The results were analyzed by descriptive statistics, the comparison between parameters by paired t-Student or Wilcoxon test as appropriate, a value of p